Interventions for Cognitive Impairment in Colorectal Cancer Patients

结直肠癌患者认知障碍的干预措施

基本信息

  • 批准号:
    8879608
  • 负责人:
  • 金额:
    $ 20.03万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-08-01 至 2017-07-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): A majority of colorectal cancer patients (78%), as demonstrated by our research and the research of others, experience chemotherapy-related cognitive impairment (CRCI); however, interventions to address CRCI in this population are lacking. Main problem areas include difficulty in memory, concentration, attention and executive function. CRCI impairs many facets of quality of life; these effects can last for years in up to 35% of survivors. The etiology of CRCI is not clearly understood, and there are no effective management approaches. Our preliminary work, and that of others, has shown that chemotherapy increases proinflammatory cytokines and that these changes are linked with cognitive impairments in cancer patients during chemotherapy, suggesting that inflammation may contribute to CRCI. If so, interventions that reduce inflammation might alleviate CRCI. Ibuprofen targets many of the same inflammatory cytokine pathways found to be increased in cancer patients, and it can delay the onset or reduce the effects of cognitive impairments in healthy individuals as well as in those at risk for cognitive diseases. Evidence suggests that exercise, which also reduces inflammation, can improve cognitive functioning in healthy adults, in patients with neurodegenerative disease, and those at risk for cognitive decline. Very preliminary research suggests exercise may improve CRCI in cancer patients. Reduction of inflammation with exercise and low-dose ibuprofen is a promising target to alleviate CRCI, particularly during chemotherapy; however, this hypothesis has not yet been tested in colorectal cancer patients. In preparation for this proposal, we conducted a small feasibility randomized clinical trial of an exercise intervention (aerobic and resistance training) and low-dose ibuprofen (200 mg twice daily) for 6 weeks in colorectal cancer patients receiving chemotherapy and showed that both of these interventions are feasible, patients can complete all measures, and that the study evokes high satisfaction. Pilot results from this study suggest that both interventions independently are promising for alleviating CRCI. This innovative R21 proposal builds upon our feasibility trial and includes a three-arm randomized controlled clinical trial comparing the influence of ibuprofen + health education (Arm 1), placebo + exercise (Arm 2) and placebo + health education (control; Arm 3) on CRCI in 84 colorectal cancer patients undergoing adjuvant chemotherapy and experiencing CRCI. The exercise and ibuprofen arms will each be compared to the control (Arm 3) with the primary goal of assessing the preliminary efficacy of each intervention for alleviating CRCI in colorectal cancer patients receiving chemotherapy. We are also assessing whether these interventions influence levels of cytokines and receptors, and whether intervention effects are mediated by inflammation. The study proposal herein is designed to provide critical preliminary information and data to inform an anticipated R01. This study would be one of the first, if not the first, clinical trial to assess interventions for CRCI in colorectal cancer patiets receiving chemotherapy. The benefit of improving CRCI as a result of this study could be considerable.
 描述(由申请人提供):正如我们的研究和其他人的研究所证明的那样,大多数结直肠癌患者(78%)经历化疗相关的认知障碍(CRCI);然而,缺乏针对该人群中CRCI的干预措施。主要问题领域包括记忆力、注意力、注意力和执行功能方面的困难。CRCI损害生活质量的许多方面;这些影响可以在高达35%的幸存者中持续多年。CRCI的病因尚不清楚,也没有有效的治疗方法。我们和其他人的初步工作表明,化疗增加了促炎细胞因子,这些变化与化疗期间癌症患者的认知障碍有关,这表明炎症可能有助于CRCI。如果是这样,减少炎症的干预措施可能会缓解CRCI。Iceland靶向许多在癌症患者中发现增加的相同炎性细胞因子途径,并且它可以延迟健康个体以及有认知疾病风险的个体中认知障碍的发作或减少其影响。有证据表明,运动也可以减少炎症,可以改善健康成年人、神经退行性疾病患者和有认知能力下降风险的人的认知功能。非常初步的研究表明,运动可以改善癌症患者的CRCI。通过运动和低剂量布洛芬减少炎症是缓解CRCI的一个有希望的目标,特别是在化疗期间;然而,这一假设尚未在结直肠癌患者中得到验证。在准备这项建议时,我们进行了一项运动干预(有氧和阻力训练)和低剂量布洛芬的小型可行性随机临床试验。 (200在接受化疗的结直肠癌患者中进行为期6周的研究,结果表明这两种干预措施都是可行的,患者可以完成所有措施,并且该研究引起了很高的满意度。这项研究的初步结果表明,这两种干预措施独立地有希望缓解CRCI。这项创新的R21提案建立在我们的可行性试验的基础上,包括一项三臂随机对照临床试验,比较了布洛芬+健康教育(第1组),安慰剂+运动(第2组)和安慰剂+健康教育(对照;第3组)对84名接受辅助化疗并经历CRCI的结直肠癌患者的CRCI的影响。将运动组和布洛芬组分别与对照组(第3组)进行比较,主要目的是评估每种干预措施缓解接受化疗的结直肠癌患者CRCI的初步疗效。我们还评估了这些干预措施是否会影响细胞因子和受体的水平,以及干预效果是否由炎症介导。本文中的研究提案旨在提供关键的初步信息和数据,以告知预期的R01。这项研究将是 第一个,如果不是第一个,临床试验,以评估干预措施,CRCI在结直肠癌患者接受 化疗作为这项研究的结果,改善CRCI的好处可能是相当大的。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michelle C Janelsins其他文献

Michelle C Janelsins的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michelle C Janelsins', 18)}}的其他基金

Optimizing Functional Outcomes of Older Survivors After Chemotherapy
优化老年幸存者化疗后的功能结果
  • 批准号:
    10434652
  • 财政年份:
    2020
  • 资助金额:
    $ 20.03万
  • 项目类别:
Translational Neuroscience Approaches to Cancer-Related Cognitive Impairment: Measurement, Mechanisms, and Function
癌症相关认知障碍的转化神经科学方法:测量、机制和功能
  • 批准号:
    10442657
  • 财政年份:
    2019
  • 资助金额:
    $ 20.03万
  • 项目类别:
Clinical and Translational Cancer Control Research Training Program
临床和转化癌症控制研究培训计划
  • 批准号:
    10425378
  • 财政年份:
    2019
  • 资助金额:
    $ 20.03万
  • 项目类别:
Translational Neuroscience Approaches to Cancer-Related Cognitive Impairment: Measurement, Mechanisms, and Function
癌症相关认知障碍的转化神经科学方法:测量、机制和功能
  • 批准号:
    10222614
  • 财政年份:
    2019
  • 资助金额:
    $ 20.03万
  • 项目类别:
Clinical and Translational Cancer Control Research Training Program
临床和转化癌症控制研究培训计划
  • 批准号:
    10646436
  • 财政年份:
    2019
  • 资助金额:
    $ 20.03万
  • 项目类别:
Translational Neuroscience Approaches to Cancer-Related Cognitive Impairment: Measurement, Mechanisms, and Function
癌症相关认知障碍的转化神经科学方法:测量、机制和功能
  • 批准号:
    10655405
  • 财政年份:
    2019
  • 资助金额:
    $ 20.03万
  • 项目类别:
Clinical and Translational Cancer Control Research Training Program
临床和转化癌症控制研究培训计划
  • 批准号:
    9788901
  • 财政年份:
    2019
  • 资助金额:
    $ 20.03万
  • 项目类别:
Clinical and Translational Cancer Control Research Training Program
临床和转化癌症控制研究培训计划
  • 批准号:
    10163131
  • 财政年份:
    2019
  • 资助金额:
    $ 20.03万
  • 项目类别:
Clinical and Translational Approaches to Cognitive Impairments in Cancer
癌症认知障碍的临床和转化方法
  • 批准号:
    8756447
  • 财政年份:
    2014
  • 资助金额:
    $ 20.03万
  • 项目类别:
Interventions Targeting Inflammation for Chemotherapy-Related Cognitive Problems
针对化疗相关认知问题的炎症干预措施
  • 批准号:
    8826705
  • 财政年份:
    2013
  • 资助金额:
    $ 20.03万
  • 项目类别:

相似海外基金

3D Engineered Model of Microscopic Colorectal Cancer Liver Metastasis for Adjuvant Chemotherapy Screens
用于辅助化疗筛选的显微结直肠癌肝转移 3D 工程模型
  • 批准号:
    10556192
  • 财政年份:
    2023
  • 资助金额:
    $ 20.03万
  • 项目类别:
Developing Digital Pathology Biomarkers for Response to Neoadjuvant and Adjuvant Chemotherapy in Breast Cancer
开发数字病理学生物标志物以应对乳腺癌新辅助和辅助化疗
  • 批准号:
    10315227
  • 财政年份:
    2021
  • 资助金额:
    $ 20.03万
  • 项目类别:
Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colorectal Cancer: A Multicentre Phase II/III Randomised Controlled Trial (DYNAMIC-III)
循环肿瘤 DNA 分析为 III 期结直肠癌辅助化疗提供信息:多中心 II/III 期随机对照试验 (DYNAMIC-III)
  • 批准号:
    443988
  • 财政年份:
    2021
  • 资助金额:
    $ 20.03万
  • 项目类别:
    Operating Grants
Establishment of new selection system for adjuvant chemotherapy of colorectal cancer
结直肠癌辅助化疗新选择体系的建立
  • 批准号:
    20K09011
  • 财政年份:
    2020
  • 资助金额:
    $ 20.03万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improved survival by Helicobacter pylori-modulated immunity in gastric cancer patients with adjuvant chemotherapy
幽门螺杆菌调节免疫力可改善接受辅助化疗的胃癌患者的生存率
  • 批准号:
    19K09130
  • 财政年份:
    2019
  • 资助金额:
    $ 20.03万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A new strategy of adjuvant chemotherapy for lung cancer based on the expression of anti-aging gene Klotho
基于抗衰老基因Klotho表达的肺癌辅助化疗新策略
  • 批准号:
    19K18225
  • 财政年份:
    2019
  • 资助金额:
    $ 20.03万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer
预测胰腺癌S-1辅助化疗效果的新候选因素
  • 批准号:
    18K16337
  • 财政年份:
    2018
  • 资助金额:
    $ 20.03万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Project 2-Metabolic Modulation of Myeloid-Derived Suppressor Cells to Increase Efficacy of Neo adjuvant Chemotherapy and Immunotherapy
项目2-骨髓源性抑制细胞的代谢调节以提高新辅助化疗和免疫疗法的疗效
  • 批准号:
    10005254
  • 财政年份:
    2018
  • 资助金额:
    $ 20.03万
  • 项目类别:
Radiogenomic tools for prediction of breast cancer neo-adjuvant chemotherapy response from pre-treatment MRI
通过治疗前 MRI 预测乳腺癌新辅助化疗反应的放射基因组学工具
  • 批准号:
    9763320
  • 财政年份:
    2018
  • 资助金额:
    $ 20.03万
  • 项目类别:
Analysis of the molecular mechanism for the prognostic biomarker of adjuvant chemotherapy
辅助化疗预后生物标志物的分子机制分析
  • 批准号:
    18K07341
  • 财政年份:
    2018
  • 资助金额:
    $ 20.03万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了